Repositioning Candidates

Repositioning candidates for NAFLD are derived from DrugBank which fall into three categories: therapeutic strategy-associated, target-associated, and indication-associated candidates. For each candidate, detailed properties are extracted from DrugBank, and related strategies, target and NAFLD-associated disease in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3

Search for:

     oxidative stress
50 records.
Candidate ID Source ID Source Type Compound Type Candidate Name Inclusion Criteria
R0041 DB00130 approved; investigational; nutraceutical small molecule L-Glutamine Therapeutic strategy associated Details
R0044 DB00134 approved; nutraceutical small molecule Methionine Therapeutic strategy associated Details
R0045 DB00137 approved; investigational; nutraceutical small molecule Lutein Therapeutic strategy associated Details
R0046 DB00138 approved; nutraceutical small molecule Cystine Therapeutic strategy associated Details
R0053 DB00152 approved; investigational; nutraceutical; vet_approved small molecule Thiamine Therapeutic strategy associated Details
R0065 DB00178 approved small molecule Ramipril Therapeutic strategy associated Details
R0088 DB00227 approved; investigational small molecule Lovastatin Therapeutic strategy associated Details
R0227 DB00641 approved small molecule Simvastatin Therapeutic strategy associated Details
R0243 DB00694 approved small molecule Daunorubicin Therapeutic strategy associated Details
R0288 DB00808 approved small molecule Indapamide Therapeutic strategy associated Details
R0359 DB00995 approved; investigational small molecule Auranofin Therapeutic strategy associated Details
R0385 DB01050 approved small molecule Ibuprofen Target associated Details
R0506 DB01381 approved; investigational; nutraceutical biotech Ginkgo biloba Therapeutic strategy associated Details
R0626 DB04854 approved small molecule Febuxostat Therapeutic strategy associated Details
R0629 DB04861 approved; investigational small molecule Nebivolol Therapeutic strategy associated Details
R0829 DB05533 investigational small molecule QR-333 Therapeutic strategy associated Details
R0843 DB05660 investigational small molecule D-JNKI-1 Therapeutic strategy associated Details
R0852 DB05719 investigational small molecule Elesclomol Therapeutic strategy associated Details
R0911 DB05983 investigational small molecule Bardoxolone methyl Therapeutic strategy associated Details
R0929 DB06137 approved; investigational small molecule Tirbanibulin Therapeutic strategy associated Details
R0933 DB06154 approved small molecule Pentaerythritol tetranitrate Therapeutic strategy associated Details
R0958 DB06250 investigational small molecule Fluasterone Therapeutic strategy associated Details
R0997 DB06376 investigational small molecule CHGN111 Therapeutic strategy associated Details
R1091 DB06755 approved; nutraceutical small molecule Beta carotene Therapeutic strategy associated Details
R1107 DB06824 approved; investigational small molecule Triethylenetetramine Therapeutic strategy associated Details
R1167 DB08838 experimental small molecule Agmatine Therapeutic strategy associated Details
R1168 DB08842 approved; investigational small molecule Acetylcarnitine Therapeutic strategy associated Details
R1169 DB08844 investigational small molecule Uric acid Therapeutic strategy associated Details
R1184 DB08908 approved; investigational small molecule Dimethyl fumarate Therapeutic strategy associated Details
R1190 DB08949 approved; withdrawn small molecule Inositol nicotinate Therapeutic strategy associated Details
R1191 DB08995 approved; investigational small molecule Diosmin Therapeutic strategy associated Details
R1302 DB09338 experimental small molecule Mersalyl Therapeutic strategy associated Details
R1327 DB11068 approved small molecule Selenic acid Therapeutic strategy associated Details
R1352 DB11217 approved small molecule Arbutin Therapeutic strategy associated Details
R1367 DB11333 approved; investigational small molecule Poloxamer 188 Therapeutic strategy associated Details
R1381 DB11590 approved small molecule Thimerosal Therapeutic strategy associated Details
R1439 DB12243 approved; investigational small molecule Edaravone Therapeutic strategy associated Details
R1441 DB12281 approved; investigational biotech Luspatercept Therapeutic strategy associated Details
R1442 DB12328 approved; investigational small molecule Cantharidin Therapeutic strategy associated Details
R1458 DB12651 investigational small molecule Bardoxolone Therapeutic strategy associated Details
R1471 DB12965 approved; investigational small molecule Silver Therapeutic strategy associated Details
R1475 DB13145 approved; investigational small molecule Nedaplatin Therapeutic strategy associated Details
R1499 DB13906 experimental biotech Aloe vera leaf Therapeutic strategy associated Details
R1505 DB13949 approved small molecule Ferric cation Therapeutic strategy associated Details
R1508 DB14001 approved; nutraceutical; vet_approved small molecule alpha-Tocopherol succinate Therapeutic strategy associated Details
R1509 DB14002 approved; nutraceutical; vet_approved small molecule D-alpha-Tocopherol acetate Therapeutic strategy associated Details
R1510 DB14003 approved small molecule alpha-Tocopherol acetate Therapeutic strategy associated Details
R1518 DB14487 approved; investigational small molecule Zinc acetate Therapeutic strategy associated Details
R1543 DB14783 approved; investigational small molecule Diroximel fumarate Therapeutic strategy associated Details
R1573 DB15726 investigational biotech Human Umbilical Cord Mesenchymal Stem Cells Therapeutic strategy associated Details